Reuters reports the FDA has shelved its Commissioner’s National Priority Voucher program, with no new vouchers issued for at least six months after the program’s champion left the agency. While the FDA has reportedly kept applications open, sources say voucher submissions are no longer moving through the accelerated-review workflow. The development matters for companies that used the voucher pathway to compress timelines for priority drugs, including both new applicants and existing voucher holders. The FDA has not provided clear guidance on how the change affects already-awarded vouchers, leaving uncertainty around timelines and engagement. For investors, the move also signals shifting regulatory acceleration practices—at a time when pipeline execution and trial timing have become central drivers of valuation.